Evidence map›Paper›PMID 40980260›Full record

ArticlePhysics and imaging in radiation oncology2025

Advancing offline magnetic resonance-guided prostate radiotherapy through dedicated imaging and deep learning-based automatic contouring of targets and neurovascular structures.

Philipp Schubert, Matthias May, Daniel Höfler, Hans-Peter Fautz, Jana Hutter, Ricarda Merten, Sina Mansoorian, Thomas Weissmann, Lisa Deloch, Miriam Schonath and 10 more

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Philipp SchubertDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Matthias MayCCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Daniel HöflerDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Hans-Peter FautzImaging Science Institute Erlangen, Siemens Healthineers, Ulmenweg 18, 91054 Erlangen, Germany.
Jana HutterCCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Ricarda MertenDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Sina MansoorianBZKF: Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Thomas WeissmannDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Lisa DelochDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Miriam SchonathDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Nathalia BelmasDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Felix GrabenbauerDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Benjamin FreyDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Udo GaiplDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Bernd-Niklas AxerDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Juliane SzkitsakDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Michael UderCCC Erlangen-EMN, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Christoph BertDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Rainer FietkauDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Florian PutzDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Erectile dysfunction (ED) affects quality of life following radiotherapy for prostate cancer. Magnetic resonance imaging (MRI) planning provides superior visualization of potency-related anatomical structures compared to computed tomography (CT), enabling improved sparing. However, contouring these structures in clinical practice is time-intensive and requires expertise. Deep learning (DL) auto-contouring with MRI simulation could make neurovascular-sparing radiotherapy more accessible. Material and Methods: High-resolution 3D T2-weighted SPACE MRI sequences (<1 mm Results: DL auto-segmentation achieved an average sDSC of 0.82 (IPA: 0.93, NVB: 0.71, PB: 0.84, CC: 0.90, PR: 0.74; SV: 0.79) and average MSD of 0.74 mm (IPA: 0.61 mm; NVB: 0.88 mm; PB: 0.63 mm; CC: 0.47 mm; PR 0.83 mm; SV: 1.01 mm). Blinded ratings showed no significant differences between DL and expert contours, except for pudendal arteries (Mean DL vs. expert; NVB: 82 vs. 85; PB: 86 vs. 88; CC: 83 vs. 88; PR 81 vs. 83; SV 78 vs. 81 all p > 0.05; IPA: 82 vs. 89; p = 0.028). Conclusion: Combining high-resolution MRI simulation with DL postprocessing enables accurate auto-contouring for MR-guided SBRT planning, potentially advancing neurovascular-sparing radiotherapy beyond current standards.

Indexed as

Auto contouringDeep learningMR-guidedNeurovascular structuresOrgans at riskProstate cancerRadiotherapySBRT

Identifiers

PMID40980260
PMCPMC12446760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.